Treatment targets in the management of dyslipidemias: Which targets in whom?

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The public health approach to prevention of atherosclerotic cardiovascular disease (ASCVD) continues to hold great potential for prevention. This approach includes diets low in saturated fats and cholesterol, maintaining desirable body weight, regular physical activity, and absence of cigarette smoking. But drug therapy is becoming more widely used. Statins have been available for treatment of elevated serum cholesterol for a quarter of a century. They have proven efficacious for reducing risk for atherosclerotic cardiovascular disease (ASCVD). They carry little toxicity, and now that some derivatives are generic, they are inexpensive. Statins have become standard of care for patients with established ASCVD. To achieve further reduction in ASCVD events through cholesterol lowering will require new combinations with older agents and development of new drugs. The future of secondary prevention lies in testing of old and new "add-on" agents. Indications for statin use in primary prevention is less clear-cut. But clinical-trial experience with statins point to enormous potential for reducing ASCVD in the population. At the same time, there are dangers of overuse and turning society into a "drug culture". To abandon the benefits of healthy lifestyles for excessive drug intervention would be unfortunate.

Original languageEnglish (US)
Pages (from-to)692-700
Number of pages9
JournalCurrent Cardiology Reports
Volume14
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Cardiovascular Diseases
Cholesterol
Pharmaceutical Preparations
Therapeutics
Primary Prevention
Standard of Care
Secondary Prevention
Hypercholesterolemia
Public Health
Smoking
Fats
Body Weight
Clinical Trials
Exercise
Diet
Drug Therapy
Serum
Population

Keywords

  • AtheroscleroticCVD
  • Bile acid sequestrants
  • CETP inhibitors
  • CKD
  • Diabetes
  • Dyslipidemia
  • Ezetimibe
  • Fibrates
  • Lifestyle
  • Metabolic syndrome
  • Nicotinic acid
  • Obesity
  • PCSK9 inhibitors
  • Physical activity
  • Secondary and primary prevention
  • Smoking
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Treatment targets in the management of dyslipidemias : Which targets in whom? / Grundy, Scott M.

In: Current Cardiology Reports, Vol. 14, No. 6, 12.2012, p. 692-700.

Research output: Contribution to journalArticle

@article{cec1576c1b074b43a8c15decaa7f5d05,
title = "Treatment targets in the management of dyslipidemias: Which targets in whom?",
abstract = "The public health approach to prevention of atherosclerotic cardiovascular disease (ASCVD) continues to hold great potential for prevention. This approach includes diets low in saturated fats and cholesterol, maintaining desirable body weight, regular physical activity, and absence of cigarette smoking. But drug therapy is becoming more widely used. Statins have been available for treatment of elevated serum cholesterol for a quarter of a century. They have proven efficacious for reducing risk for atherosclerotic cardiovascular disease (ASCVD). They carry little toxicity, and now that some derivatives are generic, they are inexpensive. Statins have become standard of care for patients with established ASCVD. To achieve further reduction in ASCVD events through cholesterol lowering will require new combinations with older agents and development of new drugs. The future of secondary prevention lies in testing of old and new {"}add-on{"} agents. Indications for statin use in primary prevention is less clear-cut. But clinical-trial experience with statins point to enormous potential for reducing ASCVD in the population. At the same time, there are dangers of overuse and turning society into a {"}drug culture{"}. To abandon the benefits of healthy lifestyles for excessive drug intervention would be unfortunate.",
keywords = "AtheroscleroticCVD, Bile acid sequestrants, CETP inhibitors, CKD, Diabetes, Dyslipidemia, Ezetimibe, Fibrates, Lifestyle, Metabolic syndrome, Nicotinic acid, Obesity, PCSK9 inhibitors, Physical activity, Secondary and primary prevention, Smoking, Statins",
author = "Grundy, {Scott M}",
year = "2012",
month = "12",
doi = "10.1007/s11886-012-0305-7",
language = "English (US)",
volume = "14",
pages = "692--700",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Treatment targets in the management of dyslipidemias

T2 - Which targets in whom?

AU - Grundy, Scott M

PY - 2012/12

Y1 - 2012/12

N2 - The public health approach to prevention of atherosclerotic cardiovascular disease (ASCVD) continues to hold great potential for prevention. This approach includes diets low in saturated fats and cholesterol, maintaining desirable body weight, regular physical activity, and absence of cigarette smoking. But drug therapy is becoming more widely used. Statins have been available for treatment of elevated serum cholesterol for a quarter of a century. They have proven efficacious for reducing risk for atherosclerotic cardiovascular disease (ASCVD). They carry little toxicity, and now that some derivatives are generic, they are inexpensive. Statins have become standard of care for patients with established ASCVD. To achieve further reduction in ASCVD events through cholesterol lowering will require new combinations with older agents and development of new drugs. The future of secondary prevention lies in testing of old and new "add-on" agents. Indications for statin use in primary prevention is less clear-cut. But clinical-trial experience with statins point to enormous potential for reducing ASCVD in the population. At the same time, there are dangers of overuse and turning society into a "drug culture". To abandon the benefits of healthy lifestyles for excessive drug intervention would be unfortunate.

AB - The public health approach to prevention of atherosclerotic cardiovascular disease (ASCVD) continues to hold great potential for prevention. This approach includes diets low in saturated fats and cholesterol, maintaining desirable body weight, regular physical activity, and absence of cigarette smoking. But drug therapy is becoming more widely used. Statins have been available for treatment of elevated serum cholesterol for a quarter of a century. They have proven efficacious for reducing risk for atherosclerotic cardiovascular disease (ASCVD). They carry little toxicity, and now that some derivatives are generic, they are inexpensive. Statins have become standard of care for patients with established ASCVD. To achieve further reduction in ASCVD events through cholesterol lowering will require new combinations with older agents and development of new drugs. The future of secondary prevention lies in testing of old and new "add-on" agents. Indications for statin use in primary prevention is less clear-cut. But clinical-trial experience with statins point to enormous potential for reducing ASCVD in the population. At the same time, there are dangers of overuse and turning society into a "drug culture". To abandon the benefits of healthy lifestyles for excessive drug intervention would be unfortunate.

KW - AtheroscleroticCVD

KW - Bile acid sequestrants

KW - CETP inhibitors

KW - CKD

KW - Diabetes

KW - Dyslipidemia

KW - Ezetimibe

KW - Fibrates

KW - Lifestyle

KW - Metabolic syndrome

KW - Nicotinic acid

KW - Obesity

KW - PCSK9 inhibitors

KW - Physical activity

KW - Secondary and primary prevention

KW - Smoking

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84870481730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870481730&partnerID=8YFLogxK

U2 - 10.1007/s11886-012-0305-7

DO - 10.1007/s11886-012-0305-7

M3 - Article

C2 - 22956441

AN - SCOPUS:84870481730

VL - 14

SP - 692

EP - 700

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 6

ER -